Although PDE‐5 inhibitors are primarily used for therapeutic management of erectile dysfunction (Porst et al., 2001), a growing body of evidence are supporting the cardioprotective role of PDE‐5 inhibitors. The gene discussed is PDE5A; the disease is erectile dysfunction.